Drug Profile
Research programme: monoclonal antibodies - Zalgen Labs
Alternative Names: Arevirumab™ - Zalgen LabsLatest Information Update: 22 Dec 2022
Price :
$50
*
At a glance
- Originator Viral Hemorrhagic Fever Consortium; Zalgen Labs
- Developer Tulane University; University of Rochester; University of Texas Medical Branch; Zalgen Labs
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Lassa fever
- No development reported Ebola virus infections; Lymphocytic choriomeningitis virus infections; Viral haemorrhagic fevers
Most Recent Events
- 22 Dec 2022 Arevirumab is still in preclinical trials for Lassa fever in the USA (Zalgen labs pipeline, December 2022)
- 28 Jul 2021 No recent reports of development identified for research development in Ebola-virus-infections in USA (Parenteral)
- 28 Jul 2021 No recent reports of development identified for research development in Lymphocytic-choriomeningitis-virus-infections in USA (Parenteral)